WO2001024817A3 - Pharmaceutical compositions of fibrinolytic agent - Google Patents

Pharmaceutical compositions of fibrinolytic agent Download PDF

Info

Publication number
WO2001024817A3
WO2001024817A3 PCT/US2000/027022 US0027022W WO0124817A3 WO 2001024817 A3 WO2001024817 A3 WO 2001024817A3 US 0027022 W US0027022 W US 0027022W WO 0124817 A3 WO0124817 A3 WO 0124817A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
fibrinolytic agent
lyophilized
agent
lyophilized composition
Prior art date
Application number
PCT/US2000/027022
Other languages
French (fr)
Other versions
WO2001024817A2 (en
Inventor
Brent S Kendrick
Brian Peterson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002385966A priority Critical patent/CA2385966A1/en
Priority to AT00967197T priority patent/ATE262923T1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to HU0202654A priority patent/HUP0202654A3/en
Priority to IL14884200A priority patent/IL148842A0/en
Priority to BR0014420-7A priority patent/BR0014420A/en
Priority to DE60009529T priority patent/DE60009529T2/en
Priority to EP00967197A priority patent/EP1220685B1/en
Priority to AU77430/00A priority patent/AU769313B2/en
Priority to NZ518007A priority patent/NZ518007A/en
Priority to MXPA02003197A priority patent/MXPA02003197A/en
Priority to EA200200396A priority patent/EA004627B1/en
Priority to SK424-2002A priority patent/SK4242002A3/en
Priority to JP2001527816A priority patent/JP2003510369A/en
Priority to SI200030404T priority patent/SI1220685T1/en
Publication of WO2001024817A2 publication Critical patent/WO2001024817A2/en
Publication of WO2001024817A3 publication Critical patent/WO2001024817A3/en
Priority to NO20021500A priority patent/NO20021500L/en
Priority to BG106578A priority patent/BG106578A/en
Priority to HK03100282.4A priority patent/HK1049112B/en
Priority to AU2004201694A priority patent/AU2004201694B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
PCT/US2000/027022 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent WO2001024817A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EA200200396A EA004627B1 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
MXPA02003197A MXPA02003197A (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent.
SK424-2002A SK4242002A3 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
AT00967197T ATE262923T1 (en) 1999-10-01 2000-09-29 PHARMACEUTICAL COMPOSITION OF FIBRINOLYTIC AGENT
BR0014420-7A BR0014420A (en) 1999-10-01 2000-09-29 Pharmaceutical composition, method for preparing a pharmaceutical composition, and, kit for preparing an aqueous pharmaceutical composition
DE60009529T DE60009529T2 (en) 1999-10-01 2000-09-29 PHARMACEUTICAL COMPOSITION OF FIBRINOLYTIC AGENT
EP00967197A EP1220685B1 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
AU77430/00A AU769313B2 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
NZ518007A NZ518007A (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of metalloproteinase fibrinolytic agent
CA002385966A CA2385966A1 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
IL14884200A IL148842A0 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
HU0202654A HUP0202654A3 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent and process for preparation thereof
JP2001527816A JP2003510369A (en) 1999-10-01 2000-09-29 Pharmaceutical composition of fibrinolytic agent
SI200030404T SI1220685T1 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent
NO20021500A NO20021500L (en) 1999-10-01 2002-03-26 Pharmaceutical preparations of fibrinolytic agent
BG106578A BG106578A (en) 1999-10-01 2002-04-04 Pharmaceutical compositions of fibronolytic agent
HK03100282.4A HK1049112B (en) 1999-10-01 2003-01-10 Pharmaceutical compositions of fibrinolytic agent
AU2004201694A AU2004201694B2 (en) 1999-10-01 2004-04-22 Pharmaceutical compositions of fibrinolytic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/411,335 1999-10-01
US09/411,335 US6440414B1 (en) 1999-10-01 1999-10-01 Pharmaceutical compositions of fibrinolytic agent

Publications (2)

Publication Number Publication Date
WO2001024817A2 WO2001024817A2 (en) 2001-04-12
WO2001024817A3 true WO2001024817A3 (en) 2001-10-18

Family

ID=23628514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027022 WO2001024817A2 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent

Country Status (28)

Country Link
US (4) US6440414B1 (en)
EP (2) EP1220685B1 (en)
JP (1) JP2003510369A (en)
KR (1) KR100717435B1 (en)
CN (2) CN100353999C (en)
AT (1) ATE262923T1 (en)
AU (1) AU769313B2 (en)
BG (1) BG106578A (en)
BR (1) BR0014420A (en)
CA (1) CA2385966A1 (en)
CZ (1) CZ20021033A3 (en)
DE (2) DE60009529T2 (en)
DK (1) DK1220685T3 (en)
EA (2) EA006600B1 (en)
ES (2) ES2218228T3 (en)
HK (1) HK1049112B (en)
HU (1) HUP0202654A3 (en)
IL (1) IL148842A0 (en)
MX (1) MXPA02003197A (en)
NO (1) NO20021500L (en)
NZ (4) NZ540967A (en)
PL (1) PL355016A1 (en)
PT (1) PT1220685E (en)
SG (1) SG148823A1 (en)
SK (1) SK4242002A3 (en)
WO (1) WO2001024817A2 (en)
YU (1) YU23302A (en)
ZA (1) ZA200202400B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634663C (en) * 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
DE10149030A1 (en) * 2001-10-05 2003-04-10 Viscum Ag Preparation of storage-stable medicaments containing recombinant carbohydrate-binding polypeptides, especially r-viscumin, useful e.g. as cytotoxic agent, comprises cooling, freezing, spray-drying or lyophilizing solution of pH more than 6
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
JP2006514914A (en) * 2002-02-14 2006-05-18 バイエル・フアーマシユーチカルズ・コーポレーシヨン Formulation strategies in the stabilization of peptides in organic solvents and in the dry state
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
NZ555503A (en) * 2004-12-15 2010-01-29 Biovitrum Ab Publ Therapeutic formulations of keratinocyte growth factor
EP1950211A4 (en) * 2005-11-18 2011-08-31 Eisai R&D Man Co Ltd Process for production of cinnamamide derivative
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2008056840A1 (en) * 2006-11-08 2008-05-15 Silla University Industry Academic Cooperation Foundation Fibrinolytic metalloprotease and composition comprising the same
EP1958618A1 (en) 2007-02-15 2008-08-20 Octapharma AG Method for freeze-drying with optimum reconstitution of biopolymers
JP5779780B2 (en) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Factor VIII formulation
CN102482338B (en) * 2009-07-10 2016-09-28 斯路姆基因公司 Plasminogen and the variant of fibrinolysin
CN102000022A (en) * 2010-11-23 2011-04-06 郑州大学 Recombined bifunctional plasmin freeze-drying preparation for injection and preparation method thereof
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
WO2016073668A1 (en) * 2014-11-06 2016-05-12 The Regents Of The University Of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
CN113382714A (en) * 2019-01-06 2021-09-10 恩多全球美学有限公司 Collagenase preparation and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083961A (en) * 1975-05-05 1978-04-11 Pierre Fabre S.A. Plasminogen activator pharmaceutical compositions
EP0624642A1 (en) * 1993-05-12 1994-11-17 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
EP0689843A1 (en) * 1993-12-17 1996-01-03 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000196A1 (en) * 1980-06-27 1982-01-21 Mitchelson D Movement measuring apparatus and landmarks for use therewith
US4447236A (en) 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4848700A (en) * 1987-04-16 1989-07-18 Lockheed John A Canard control system for aircraft
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
JPH05184352A (en) 1990-01-16 1993-07-27 Centro De Ing Genetica Y Biotecnol Method for expressing dissimilar gene in pichia pastoris yeast, expression vector and transforming microorganism
US5709676A (en) 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
US5370653A (en) 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
US5626564A (en) 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US6020181A (en) 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997045105A1 (en) 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US20020081685A1 (en) 2000-08-03 2002-06-27 Fox Brian A. Disintegrin homologs, ZSNK10, ZSNK11, and ZSNK12

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083961A (en) * 1975-05-05 1978-04-11 Pierre Fabre S.A. Plasminogen activator pharmaceutical compositions
EP0624642A1 (en) * 1993-05-12 1994-11-17 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
EP0689843A1 (en) * 1993-12-17 1996-01-03 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POTEMPA J ET AL: "STABILIZATION VS. DEGRADATION OF STAPHYLOCOCCUS-AUREUS METALLOPROTEINASE", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 993, no. 2-3, 1989, pages 301 - 304, XP000992761, ISSN: 0006-3002 *

Also Published As

Publication number Publication date
EA004627B1 (en) 2004-06-24
CN100353999C (en) 2007-12-12
ES2224917T1 (en) 2005-03-16
DE60009529D1 (en) 2004-05-06
KR20020053065A (en) 2002-07-04
EP1220685A2 (en) 2002-07-10
HK1049112A1 (en) 2003-05-02
HUP0202654A3 (en) 2003-11-28
US20060263347A1 (en) 2006-11-23
DE60009529T2 (en) 2005-04-14
PT1220685E (en) 2004-08-31
YU23302A (en) 2005-06-10
NZ530959A (en) 2005-08-26
DK1220685T3 (en) 2004-08-02
CA2385966A1 (en) 2001-04-12
EA006600B1 (en) 2006-02-24
EA200200396A1 (en) 2002-10-31
AU7743000A (en) 2001-05-10
US7244426B2 (en) 2007-07-17
NO20021500D0 (en) 2002-03-26
IL148842A0 (en) 2002-09-12
PL355016A1 (en) 2004-03-22
NO20021500L (en) 2002-05-27
DE04007657T1 (en) 2005-01-13
NZ550200A (en) 2008-04-30
US7138114B2 (en) 2006-11-21
US7311908B2 (en) 2007-12-25
NZ518007A (en) 2004-03-26
ZA200202400B (en) 2003-05-28
CN101209347A (en) 2008-07-02
EP1220685B1 (en) 2004-03-31
MXPA02003197A (en) 2002-09-30
US20060246053A1 (en) 2006-11-02
HUP0202654A2 (en) 2002-12-28
EP1438967A2 (en) 2004-07-21
ES2218228T3 (en) 2004-11-16
NZ540967A (en) 2007-02-23
CZ20021033A3 (en) 2003-06-18
HK1049112B (en) 2005-01-21
KR100717435B1 (en) 2007-05-14
EA200400182A1 (en) 2004-08-26
ATE262923T1 (en) 2004-04-15
EP1438967A3 (en) 2005-01-26
BG106578A (en) 2003-04-30
BR0014420A (en) 2002-06-11
CN1402641A (en) 2003-03-12
JP2003510369A (en) 2003-03-18
SG148823A1 (en) 2009-01-29
US20020192207A1 (en) 2002-12-19
AU769313B2 (en) 2004-01-22
SK4242002A3 (en) 2003-08-05
US6440414B1 (en) 2002-08-27
WO2001024817A2 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
WO2001024817A3 (en) Pharmaceutical compositions of fibrinolytic agent
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
AU7960200A (en) Sealing composition and sealing method
HUP0103341A2 (en) Azetidine derivatives, preparation and pharmaceutical compositions thereof
CA2258606A1 (en) Crystal form ii of clarithromycin
AU7072200A (en) Fast-acting formulation components, compositions and laundry methods employing same
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU7294098A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HK1047584A1 (en) Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process.
HUP0203821A3 (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing same
HUP9701437A3 (en) Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive enzymes, pharmaceutical compns. and kits
WO2001032181A3 (en) Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
AU4045899A (en) Pyrrole derivatives, preparation method and pharmaceutical compositions containing same
EP2017269A9 (en) A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof
ZA200110150B (en) Streptogramin derivatives, preparation and compositions containing them.
AU4996100A (en) (s,r) formoterol methods and compositions
WO2000059831A3 (en) Cleavable, water-soluble surfactants
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
AU7102700A (en) Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
AU1391595A (en) Pharmaceutical compositions comprising hirudin
WO2001015777A8 (en) Pulmonary-administration of mineral ascorbates
AU6438200A (en) Low-dose, soluble builder

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-233/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 77430/00

Country of ref document: AU

Ref document number: 148842

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2002-1033

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2000967197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/02400

Country of ref document: ZA

Ref document number: PA/a/2002/003197

Country of ref document: MX

Ref document number: 4242002

Country of ref document: SK

Ref document number: 2385966

Country of ref document: CA

Ref document number: 518007

Country of ref document: NZ

Ref document number: 200202400

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2001 527816

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027004128

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 106578

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200200396

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 008163790

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027004128

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000967197

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-1033

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 518007

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2000967197

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 77430/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 518007

Country of ref document: NZ